Literature DB >> 27553618

The impact of 2015 neuromyelitis optica spectrum disorders criteria on diagnostic rates.

Shahd Hm Hamid1, Liene Elsone1, Kerry Mutch1, Tom Solomon2, Anu Jacob1.   

Abstract

BACKGROUND: The international panel for neuromyelitis optica (NMO) diagnosis has proposed diagnostic criteria for neuromyelitis optica spectrum disorders (NMOSD).
OBJECTIVES: We assessed the impact of these criteria on diagnostic rates in a large cohort of patients.
METHODS: We identified and applied the 2006 and 2015 criteria to all patients ( n = 176) seen in the NMO and non-multiple sclerosis central nervous system demyelination clinic (part of the UK NMO service) from January 2013 to May 2015.
RESULTS: The 2006 criteria classified 63 of 176 (36%) patients as NMO. A total of 42 patients (67%) were aquaporin 4 (AQP4) immunoglobulin G (IgG) +ve and 21 (33%) AQP4 IgG -ve. The 2015 criteria classified 111 of 176 (63%) patients as NMOSD, of which 81 (73%) were AQP4 IgG +ve and 30 (27%) were AQP4 IgG -ve. There was an increase of 48 patients (76%) diagnosed as NMOSD using the new criteria.
CONCLUSION: Application of the 2015 criteria led to a rise in diagnosis of NMOSD by 76%. The rise in the AQP4 IgG +ve group contributed 62% and the seronegative group contributed 14%.

Entities:  

Keywords:  Neuromyelitis optica spectrum disorders; central nervous system demyelination; criteria; multiple sclerosis

Mesh:

Substances:

Year:  2016        PMID: 27553618     DOI: 10.1177/1352458516663853

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  15 in total

1.  Seizures and Encephalitis in Myelin Oligodendrocyte Glycoprotein IgG Disease vs Aquaporin 4 IgG Disease.

Authors:  Shahd H M Hamid; Dan Whittam; Mariyam Saviour; Amal Alorainy; Kerry Mutch; Samantha Linaker; Tom Solomon; Maneesh Bhojak; Mark Woodhall; Patrick Waters; Richard Appleton; Martin Duddy; Anu Jacob
Journal:  JAMA Neurol       Date:  2018-01-01       Impact factor: 18.302

Review 2.  Neuromyelitis optica spectrum disorders.

Authors:  Saif Huda; Dan Whittam; Maneesh Bhojak; Jayne Chamberlain; Carmel Noonan; Anu Jacob
Journal:  Clin Med (Lond)       Date:  2019-03       Impact factor: 2.659

Review 3.  What's new in neuromyelitis optica? A short review for the clinical neurologist.

Authors:  Daniel Whittam; Martin Wilson; Shahd Hamid; Geoff Keir; Maneesh Bhojak; Anu Jacob
Journal:  J Neurol       Date:  2017-03-13       Impact factor: 4.849

Review 4.  Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein associated disorder-optic neuritis: a comprehensive review of diagnosis and treatment.

Authors:  Sidney M Gospe; John J Chen; M Tariq Bhatti
Journal:  Eye (Lond)       Date:  2020-12-15       Impact factor: 3.775

5.  What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients.

Authors:  Shahd H M Hamid; Daniel Whittam; Kerry Mutch; Samantha Linaker; Tom Solomon; Kumar Das; Maneesh Bhojak; Anu Jacob
Journal:  J Neurol       Date:  2017-08-24       Impact factor: 4.849

6.  A Rare Presentation of Neuromyelitis Optica Spectrum Disorders.

Authors:  Navneet K Singh; Alexander J Sweidan; Sarah Strube; Ignacio Carrillo-Nunez
Journal:  Clin Med Insights Case Rep       Date:  2018-02-05

Review 7.  Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis.

Authors:  Nadja Borisow; Masahiro Mori; Satoshi Kuwabara; Michael Scheel; Friedemann Paul
Journal:  Front Neurol       Date:  2018-10-23       Impact factor: 4.003

Review 8.  Neuromyelitis optica spectrum disorders: still evolving and broadening.

Authors:  Kazuo Fujihara
Journal:  Curr Opin Neurol       Date:  2019-06       Impact factor: 5.710

Review 9.  Spinal Cord Involvement in MS and Other Demyelinating Diseases.

Authors:  Mariano Marrodan; María I Gaitán; Jorge Correale
Journal:  Biomedicines       Date:  2020-05-22

Review 10.  Complexity and wide range of neuromyelitis optica spectrum disorders: more than typical manifestations.

Authors:  Jinming Han; Meng-Ge Yang; Jie Zhu; Tao Jin
Journal:  Neuropsychiatr Dis Treat       Date:  2017-10-20       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.